A FIRST-IN-CLASS IMMUNOTHERAPY

AGAINST CANCER AND INFECTIOUS DISEASES

Altevax is committed to bringing its innovative anticancer and anti-infectious technology to patients, to treat diseases that have no available cure today

Altevax is supported by:

aphp-logo-blue.png
Universite_Paris_logo_horizontal_edited.
logoUSPN-site-1-1.png
bpi.png
logo-agoranov-brand-business-incubator-t

Pr Antoine Carpentier

Co-founder – Scientific Advisor

 

INNOVATION

Using melanin as an adjuvant, Altevax has developed an immunotherapy that triggers a strong antigen-specific immune response of CD8+ and CD4+ T cells

Applications in cancer (preclinical phase) and infectious diseases (R&D phase)

A treatment that can be produced simply at a reasonable cost

Patented technologies:
EU patent EP 3 380 120 B1
US patent US10,857,227B2 and other patents pending

First results in humans expected in 2023

TECHNOLOGY

HOW IT WORKS AND FIRST RESULTS

In many cases of cancer or infections, the main reason for the onset of the disease is the lack of a specific immune response. As a result, many therapies currently under development to treat these diseases (immunotherapies) aim at triggering the patient's immunity and mobilize their immune system.

Altevax immunotherapy triggers an immunity that...
...is fast...

T-cell response in mice splenocytes

(nb of spots per 5x10  cells)

5

...long lasting....

T-cell response in mice splenocytes

(nb of spots per 5x10  cells)

5

...can be induced with peptides from different antigens and with various lengths...

T-cell response in mice splenocytes

(nb of spots per 5x10  cells)

5

...is between 6 to 30 times more efficient than current benchmark...
...and can eliminate tumours in cancer models

T-cell response in mice splenocytes

(nb of spots per 5x10  cells)

5

Dose of peptide (gp100µg)

Control Group (Saline)

No tumour reduction

pOVA30-IFA + CpG

Small tumour reduction and no cured mice

pOVA30-Mel + CpG (Altevax)

Significant tumour reduction and 25% cured mice

 

Unlike most current immunotherapies, Altevax technology combines efficiency and specificity

TECHNOLOGY

MAIN ADVANTAGES

Altevax technology allows to rapidly develop therapies against many diseases, leading to treatments that are easy to produce and administer

Altevax diagram 2.png
  • The technology works with a wide range of peptide lengths, allowing for optimization between reactivity, specificity and manufacturability

  • Resulting treatments will have a much lower global cost (R&D + production) than alternatives of similar efficacy - such as autologous CAR-T therapies or last generation antiviral treatments

  • Melanin, the key ingredient, can be manufactured and combined with a specific peptide at a reasonable cost - process also patented by Altevax

 
 

ACHIEVEMENTS

TECHNOLOGY

The Altevax immunotherapy is in advanced preclinical stage across several disease models, having reached key milestones on the critical path for ANSM/EMA approval for clinical trials:
  • Proof of concept - testing with consistently positive results on large number of samples (humanised mice) with wide range of peptides proving priming of CD8+ and CD4+ T cells

  • Characterisation of melanin, optimisation of the purification methods (> 99%)

  • Optimisation of the drug formulation and scale-up synthesis leading to a new patent filed (February 2020)

  • Identification of target peptides for glioblastoma (GBM)

 

TECHNOLOGY

IP AND RELEVANT SCIENTIFIC PUBLICATIONS

Altevax holds several patents and protects its technology and its use in diverse applications
  • Altevax is the exclusive worldwide licensee for the melanin technology patent
  • Already accepted in the US (patent US10,857,227B2) and the EU (patent EP 3 380 120 B1)
  • Patent family protects the combination of melanin with an antigen and its use to induce an immune response
  • Altevax also filed a patent application in February 2020 to protect the production method for its immunotherapy
Relevant scientific publications:
 

THERAPEUTIC AREAS

APPLICATION & DEVELOPMENT STRATEGY

Over the last ten years, immunotherapy has greatly transformed the treatment of certain types of cancer. But the most advanced therapies stimulate the immune system in general and are not specific to the targeted disease. They are therefore difficult to control and have side effects.

Altevax is developing a novel immunotherapy using melanin as an adjuvant, linked to a peptide that is specific to the targeted disease. The revolutionary innovation lies in this unique combination, which offers both strong stimulation and high specificity. This gives the Altevax technology the potential to develop effective treatments for various types of cancer and for infectious diseases.

This new technology could revolutionize the field of immunotherapy.

RoadMap_0821.jpg
 

THERAPEUTIC AREAS

CANCER IMMUNOTHERAPY

Professor Antoine Carpentier has been working on glioblastoma for over 15 years. He discovered the immunostimulating power of melanin while working on this particularly aggressive brain cancer.

  • Today, glioblastoma treatment relies on surgery + radiotherapy + chemotherapy (temozolomide)

  • All current therapeutic approaches to glioblastoma under clinical investigation target natural cellular mechanisms that are shown to be misregulated in certain cancer cells. These approaches are thus non specific and tricky to balance as these mechanisms are also used by normal cells.

  • By stimulating the immune response against a peptide specific to glioblastoma, the Altevax approach mimics a physiological immune response, which most likely makes it specific, effective and well tolerated.

GLIOBLASTOMA KEY FACTS
  • The most malignant among brain cancers, with a poor prognosis: survival rate of less than 5% within 5 years of diagnosis; life expectancy after diagnosis of 12-18 months.
     

  • No cure is available today, or in development. Palliative treatments are heavy for patients, have side effects and are expensive (cost of about $150,000/patient in the US including surgery)
     

  • GBM incidence is 2-3 new cases per 100,000 people per year, translating into about 80,000 new cases/year in the most developed countries. This incidence varies by country: about 14,000 cases/year in the US/Canada, 16,000 in the EU, 25,000 in China and 3,500 in Japan. The number of new cases in these countries is growing at an average 3% per year.
     

  • Total GBM market today estimated at $1.2 Billion*, growing at a 7.4% cagr* to reach over $3.5 Billion by 2035

                                                                                                                                  * Source: GlobalData GBM Study 2018

 
antoine3.jpeg

THERAPEUTIC AREAS

ANTI-INFECTIOUS TREATMENTS

The main role of the immune system is to fight infection by external pathogens. This process is well known and documented, and it is by far the most efficient way available today to fight some infectious diseases, especially those due to viruses and parasites. There are still many viral infections without an effective cure and the Covid-19 epidemic has demonstrated, if proof were needed, that innovative antiviral treatments are required. While broadly used to treat cancer, immunotherapy approaches could be used efficiently to treat viral infections. Especially if, like the Altevax technology, such approach is highly specific to the targeted pathogen.

Altevax is currently carrying out preclinical trials on malaria, with preliminary data showing that the melanin-based adjuvant can trigger an efficient immune response against the parasite.

Once the melanin-adjuvant innovation proves to be effective in humans, Altevax is planning to rapidly pursue the development of its technology in an infectious model, by partnering with a company or laboratory with expertise and history in the field of anti-infectious treatments. 

In the case of an outbreak of new pathogens, the Altevax technology could allow the rapid development of treatments, which are efficient tools that are complementary to a vaccine strategy

 
_DSC7464.JPG
 

OUR PEOPLE

ALTEVAX

IN THE NEWS

Altevax, an innovative immunotherapy against glioblastoma
Capture d’écran 2021-05-31 à 18.02.52.
 

CONTACT US

Contacts

Victor Vadaneaux - CEO
victor.vadaneaux@altevax.com
+ 33 7 56 96 03 40

Sylvie Delassus - Media Relations

syl.delassus@gmail.com

+ 33 6 26 54 33 18

LinkedIn